相关临床试验
23
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
4.3%
已完成
17
73.9%
招募中
5
21.7%
暂无批准数据
- Insulet Corporation reported second quarter 2026 revenue of $801.7 million, up 23.5% (22.7% in constant currency), exceeding the high end of its guidance range of 20%–22%. - Total Omnipod revenue reached $795.9 million, rising 24.6%, driven by 20.1% growth in U.S. Omnipod revenue and 35.5% growth internationally. - Net income climbed to $95.0 million, or $1.37 per diluted share, compared to $22.5 million, or $0.32 per diluted share, in the prior year. - Adjusted net income of $115.0 million, or $1.66 per diluted share, increased 37.4% and 41.5%, respectively, versus the prior year.
- Insulet Corporation has issued a voluntary recall of specific lots of Omnipod 5 insulin patch pumps due to small tears in internal tubing that can cause insulin leakage inside the device rather than delivery to the body. - The company has reported 18 serious adverse events associated with high blood glucose levels, including hospitalizations and diabetic ketoacidosis, though no deaths have been reported. - The recall affects approximately 1.5% of Insulet's annual global Omnipod 5 production, with the company expecting to incur up to $40 million in associated costs this year. - Insulet is providing free replacement pods to affected customers and has implemented manufacturing process updates and quality control improvements following an investigation.
- The FDA granted 510(k) clearance for an updated Omnipod 5 algorithm that allows users to set target glucose as low as 100 mg/dL, expanding customization options to six settings between 100-150 mg/dL. - The enhanced algorithm is designed to keep users in automated mode with fewer interruptions, including during prolonged high glucose events, improving the overall diabetes management experience. - Real-world evidence demonstrates that lowering glucose targets is associated with increased time in range without clinically meaningful changes in time below range. - The updated system is expected to launch in the United States during the first half of 2026, further strengthening Insulet's position in the automated insulin delivery market.
- Insulet shared real-world glycemic outcomes data from over 23,000 people with type 2 diabetes using the Omnipod 5 automated insulin delivery system in the United States. - New analysis from the SECURE-T2D pivotal trial demonstrated that Omnipod 5 significantly reduced diabetes distress in adults with type 2 diabetes over 13 weeks. - More than 30% of new patient starts in Q1 2025 were people with type 2 diabetes, reflecting growing adoption since FDA expanded indication in August 2024. - The company is advancing development of next-generation hybrid closed-loop and fully closed-loop systems, with plans to begin second EVOLUTION studies for type 2 diabetes in the second half of 2025.
- Visby Medical raised approximately $55 million with potential to reach $65 million in funding led by Catalio Capital Management to accelerate launch of its FDA-authorized at-home Women's Sexual Health Test. - The company's diagnostic platform delivers laboratory-grade PCR results within 30 minutes through a single-use, disposable test that connects to a smartphone app for seamless telemedicine consultation. - Industry veterans Isaac Ro and Chuck Alpuche joined the board to enhance operational capabilities and manufacturing scale-up as the product launches in July 2025 through direct-to-consumer channels.
- The global diabetes care market is expected to grow from $34.51 billion in 2025 to $62.73 billion by 2032, representing a compound annual growth rate of 8.9%. - Rising diabetes prevalence, with 589 million adults currently living with diabetes globally and projections reaching 853 million by 2045, is driving market expansion. - Continuous glucose monitoring devices and AI-powered diabetes management tools are gaining significant traction, with companies like Abbott and Medtronic partnering to develop integrated automated insulin delivery systems. - Type 2 diabetes accounts for nearly two-thirds of the global diabetes care market share, while North America maintains market dominance with $14.87 billion in revenue expected for 2025.
• The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements. • Connected inhalers are gaining significant traction for respiratory and neurological conditions, with recent partnerships like Modivcare and Tenovi deploying Adherium's Hailie smart inhalers to improve patient care. • Injectable smart delivery systems dominated the market with a $7.6 billion valuation in 2024, while North America leads regional adoption with $5.5 billion in revenue, expected to reach $22.2 billion by 2034.
- Abbott Laboratories has received FDA approval for an Investigational Device Exemption to evaluate its Coronary Intravascular Lithotripsy System in patients with severely calcified coronary artery disease. - The TECTONIC CAD IVL Trial will enroll up to 335 U.S. patients, using high-energy sound pressure waves to modify calcification before stent placement, potentially improving outcomes for complex CAD cases. - This strategic move positions Abbott in the highly competitive IVL market, following Johnson & Johnson's $13 billion acquisition of Shockwave Medical in 2024 and Boston Scientific's recent entry through its Bolt Medical acquisition.
• Insulet's tubeless Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia and will soon launch in Belgium, Canada, and Switzerland, expanding access to thousands more diabetes patients globally. • The system integrates with continuous glucose monitors from Dexcom (G6 and G7) and Abbott's FreeStyle Libre 2 Plus, automatically adjusting insulin delivery every five minutes using SmartAdjust technology. • Insulet plans further expansion to five additional Middle Eastern markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, strengthening its global leadership position in automated insulin delivery technology.
